Evidence map›Paper›PMID 26631609›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2016

Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations.

Yoshitsugu Mitani, Bin Liu, Pulivarthi H Rao, Vishnupriya J Borra, Mark Zafereo, Randal S Weber, Merrill Kies, Guillermina Lozano, P Andrew Futreal, Carlos Caulin and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 1 pooled it
18.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 1 synthesis or guideline pooled it, 197 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2016
    Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Molecular pathology of adenoid cystic carcinoma.Histology and histopathology · 2025
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yoshitsugu MitaniDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bin LiuDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pulivarthi H RaoDepartment of Pediatrics, Baylor College of Medicine, Houston, Texas.
Vishnupriya J BorraDepartment of Pediatrics, Baylor College of Medicine, Houston, Texas.
Mark ZafereoDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Randal S WeberDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Merrill KiesDepartment of Thoracic/Head and Neck Medicine Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Guillermina LozanoDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
P Andrew FutrealDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Carlos CaulinDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. anaggar@mdanderson.org ccaulin@mdanderson.org.
Adel K El-NaggarDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. anaggar@mdanderson.org ccaulin@mdanderson.org.
Baylor College of Medicine · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MYERS, JEFFREY NICHOLAS · 2002 to 2012
$26.1M
Molecular and Epidemiologic Characterization of Salivary Gland CarcinomasU01DE019765 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EL-NAGGAR, ADEL K. · 2009 to 2013
$6.9M
Role of MYB and MYB-NFIB fusions in Salivary Adenoid Cystic CarcinomaR21DE023656 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CAULIN, CARLOS · 2014 to 2015
$440k
NCI NIH HHS NCI CA-16672NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA097007NIDCR NIH HHS HHSN268200900039CNIDCR NIH HHS R21 DE023656NIDCR NIH HHS R21DE023656NIDCR NIH HHS U01 DE019765NIDCR NIH HHS U01DE019765PHS HHS HHSN268200900039C 04
6 · The paper itself

Abstract

purposeAdenoid cystic carcinoma (ACC) is an indolent salivary gland malignancy, characterized by t(6;9) translocations and MYB-NFIB gene fusions in approximately 50% of the tumors. The genetic alterations underlying t(6;9)-negative and t(6;9)-positive/MYB-NFIB fusion-negative ACC remain unknown. To uncover the genetic alterations in ACC lacking the canonical translocation and fusion transcript and identify new abnormalities in translocation positive tumors. EXPERIMENTAL

designWe performed whole-genome sequencing in 21 salivary ACCs and conducted targeted molecular analyses in a validation set (81 patients). Microarray gene-expression data were also analyzed to explore the biologic differences between fusion positive and negative tumors.

resultsWe identified a novel MYBL1-NFIB gene fusion as a result of t(8;9) translocation and multiple rearrangements in the MYBL1 gene in 35% of the t(6;9)-negative ACCs. All MYBL1 alterations involved deletion of the C-terminal negative regulatory domain and were associated with high MYBL1 expression. Reciprocal MYB and MYBL1 expression was consistently found in ACCs. In addition, 5'-NFIB fusions that did not involve MYB/MYBL1 genes were identified in a subset of t(6;9)-positive/fusion-negative tumors. We also delineated distinct gene-expression profiles in ACCs associated with the length of the MYB or MYBL1 fusions, suggesting a biologic importance of the C-terminal part of these fusions.

conclusionsOur study defines new molecular subclasses of ACC characterized by MYBL1 rearrangements and 5'-NFIB gene fusions.

Indexed as

Translocation, GeneticCarcinoma, Adenoid CysticChromosome BreakpointsChromosomes, Human, Pair 8Chromosomes, Human, Pair 9Cluster AnalysisFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene OrderGenome, HumanGenomicsHigh-Throughput Nucleotide SequencingHumansMaleNFI Transcription FactorsMYBL1 protein, humanNFIB protein, humanNFI Transcription FactorsOncogene Proteins, FusionProto-Oncogene ProteinsTrans-Activators

Identifiers

PMID26631609
PMCPMC4807116
OpenAlexW2185318137

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.